The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. Disease burden due to HZ was assessed as high or rather high in 70% of the patients. By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation (P = 0.009). Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ (P = 0.007). Our data indicate that VZV reactivation after ASCT is a frequent event carrying a significant disease burden and it is associated with improved survival. Low levels of specific VZV antibodies at ASCT suggest increased vulnerability for VZV reactivation.
INTRODUCTION
Herpes Zoster (HZ) is caused by reactivation of a varicella zoster virus (VZV) infection. 1 After primary infection, VZV persist in sensory dorsal root ganglia and may be reactivated in periods of diminished T-cell immunity. 2, 3 Clinical symptoms typically comprise localized vesicular skin lesions usually limited to unilateral dermatomes, fever and pain which can persist after disappearance of the skin lesions. On average, the risk for HZ is 0.12-0.76% per year in the general European population. HZ is common after allogeneic or autologous BM or peripheral blood hematopoietic SCT. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The incidence of HZ at 1 year following autologous SCT (ASCT) varies from 8 to 30%. 3, 11, [14] [15] [16] However, little is known about the incidence of HZ specifically in myeloma patients undergoing ASCT.
Myeloma induction treatment has fundamentally changed within the last decade with the availability of novel agents including thalidomide, lenalidomide and bortezomib. In contrast, most published studies reporting on the incidence of HZ in myeloma patients investigated cohorts of patients treated with the vincristin, adriamycin and dexamethasone induction regimen, the standard treatment before the novel agent era. Thus, data are largely missing on the incidence of HZ in myeloma patients after ASCT treated with current induction regimens.
Divergent recommendations for antiviral prophylaxis in ASCT patients have been reported. 2, 3, [17] [18] [19] [20] Clearly, live attenuated VZV vaccination is contraindicated in severely immunocompromised patients undergoing ASCT. In general, patients routinely receive oral antiviral prophylaxis after ASCT to reduce the risk of herpes virus-associated diseases, including HZ. The duration of prophylaxis, however, varies greatly between transplant centers. 20 At our center, we followed a restrictive strategy limiting oral antiviral prophylaxis to 3 weeks after ASCT during the study period. In this analysis, we report on the incidence and the subjective disease burden of HZ in a large single-center cohort of consecutive myeloma patients uniformly treated with high-dose melphalan and ASCT in first remission while applying a consistent restrictive oral antiviral prophylaxis. We also aimed to identify myeloma patients at an increased risk of developing HZ after ASCT. Finally, no data are available so far on the prognostic significance of HZ in myeloma patients, and this study intended to clarify this issue.
PATIENTS AND METHODS Patients
This is a single-center study investigating all consecutive adult multiple myeloma patients in first remission undergoing high-dose melphalan chemotherapy followed by autologous SCT between January 2005 and December 2011 at the University Hospital Bern, Switzerland. This study was approved by the local ethics committee of Bern, Switzerland. We determined incidence, clinical presentation and subjective disease burden of HZ using medical charts and questionnaires for patients alive. Nonresponding patients were reminded and ultimately approached by phone.
Definition of HZ
A suspected case of HZ was defined as a new-onset rash characteristic of HZ (unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution and no alternative diagnosis. Specific laboratory findings strongly suggesting HZ comprised vesicular swabs positive for VZV by PCR, culture or immunohistochemical staining. Postherpetic neuralgia was defined by the presence of HZ-associated 'worst' pain persisting or appearing after onset of a HZ rash.
Specific VZV laboratory testing
Prospectively stored blood samples taken during stem cell collection immediately preceding ASCT were analyzed together in 2013 using the Serion ELISA classic VZV IgG test kit (Institut Virion, Serion GmbH, Wuerzburg, Germany) and the immunofluorescence assay (Merifluor VZV IgG IFA kit, Meridian Bioscience Inc, London, UK) for the detection of VZV specific IgG antibodies by the indirect fluorescent antibody approach according to the manufacturer's instructions.
The immunofluorescence test to determine the VZV status is based on dilution of the patient serum: absence of fluorescent cells at the dilution of 1:10 was counted as negative, reactions at 1:10 or 1:20 were considered borderline, and serum positive at 1:40 dilution or greater was considered positive. Two independent investigators analyzed all samples by microscopy, and positive and negative controls were run in parallel.
The Serion Elisa classic VZV IgG test is based on the ELISA method. The signal intensity was assessed in international units: results o50 IU/mL were considered negative, between 50 and 100 IU/mL as borderline, and 4100 IU/mL as positive. Positive and negative controls were consistently run in parallel.
Myeloma treatment
Treatment guidelines at our center evolved during the study period. Until 2 was used for high-dose chemotherapy, and at least 2 × 10^6 CD34+ cells per kg body weight were re-infused. Antiviral prophylaxis comprised 500 mg of oral acyclovir twice daily starting on the first day after ASCT and continued for 3 weeks. In patients with limiting oral mucositis, temporary interruption of oral acyclovir treatment or change to intravenous administration was decided on an individual basis. Oral antifungal prophylaxis with fluconazole 400 mg once a week and PcP prophylaxis with trimethoprim/sulfamethoxazole three times a week were given for 3 weeks. No routine antibiotic prophylaxis was administered.
Statistics
The IBM SPSS Statistic 21.0 program (IBM, Armonk, NY, USA) was used. The log rank test was applied to identify differences between event-time distributions. In cases of non-Gaussian data distribution, the Kruskal-Wallis test was used to identify risk factors for HZ. Chi-square statistics were used to compare categorical variables. The Kaplan-Meier method was applied to calculate OS defined as the time from the day of transplantation to the date of last follow-up or death, and relapse-free survival defined as the time from the day of transplantation to first progression of myeloma, last follow-up or date of death, whichever occurred first. In patients with tandem ASCT, the second ASCT was used as day 0 for this study. A Cox proportional-hazard regression was performed for all Kaplan-Meier analyses. A Po0.05 was considered significant, and all tests were twosided. All time references were calculated from the day of transplantation.
RESULTS

Patient characteristics
Between January 2005 and December 2011, 193 myeloma patients had ASCT after high-dose melphalan chemotherapy consolidating first-line treatment. Data-cut was 31 March 2012. Two patients were lost to follow-up and excluded from the study; 191 patients were therefore available for analysis. The patient characteristics are presented in Table 1 . The mean follow-up was 27 months. Thirty-nine patients of the entire cohort have died because of myeloma progression. The remaining 152 patients filled out the HZ-specific questionnaire (return rate 100%). Information on the occurrence of HZ was available for all patients alive for the period of at least 12 months after ASCT. None of the patients in our cohort received specific VZV (re-)vaccination during induction treatment, before ASCT or within the first 12 months after ASCT.
We found that 134 of 191 patients (70%) never had HZ, and 41 (21.5%) patients had at least one HZ episode after ASCT. Sixteen (8.5%) patients had HZ before ASCT; 11 of these 16 patients had HZ during the preceding myeloma induction chemotherapy, and the remaining 5 patients had a HZ episode before the start of myeloma treatment. One patient had a HZ event both before and after autologous transplantation.
The individual time point of HZ in relation to ASCT is depicted in Figure 1a , and the cumulative incidence of HZ after ASCT treating death without HZ as a competing risk is demonstrated in Figure 1b . It indicates that the median onset of HZ is 8 months after ASCT. HZ events ranged from 24 months before to 62 months after ASCT. Twenty-six (63%) of all HZ events occurred within the first 12 months, thus the incidence of HZ in the first year after ASCT was 13.6% (26 of 191 patients). The clinical characteristics of patients with HZ compared with those without HZ are summarized in Table 1 . Remarkably, we observed that myeloma patients with HZ before ASCT had the lowest leukocyte levels following chemotherapy and G-CSF mobilization on the day of stem cell apheresis (P = 0.004). Seven patients died within the first 12 months after ASCT, with two of them having a HZ event after ASCT.
Quality of life assessment
The burden of HZ was considered as 'strong' by 37% (17) of the patients with HZ events, 'rather strong' by 33% (15) , 'a little wearing' by 28% (13) and 'harmless' by 2% (1). The pain associated with HZ was described as 'strong and long lasting' by 39% (18) of the patients with HZ, 'modest and temporary' by 41% (19) and 20% (9) indicated that they never had HZ-associated pain (Table 2) .
Patients were asked-based on their history of infections since ASCT-how they considered their immune defense since ASCT. Significantly more patients with HZ events considered their immune defense to be 'reduced' compared with patients without HZ (62.9% versus 36.5%, respectively; (P = 0.006)).
Finally, 21.1% (32) of all patients considered the concept of a prophylactic VZV vaccination 'reasonable and preferable', 52.6% (79) felt that VZV vaccination should 'at least be discussed', 20.4% (31) had 'no opinion on this matter' and 5.9% (9) patients considered VZV vaccination 'unnecessary'. Acceptance of a prophylactic VZV vaccination was higher among patients with HZ than in patients without HZ (P o 0.0001).
Survival
We investigated whether the occurrence of HZ after ASCT for myeloma was associated with a specific outcome. We calculated Kaplan-Meier OS rates comparing patients with HZ after ASCT to patients without HZ after ASCT (Figure 2 ). The median OS was not reached in the 41 patients with HZ after ASCT, whereas it was 87 months for the 150 myeloma patients without HZ after ASCT (P = 0.007). The Cox proportional-hazard regression for OS (Table 3) indicates that HZ is an independent factor for better survival. The same was observed for ISS stage at diagnosis and for the use of bortezomib during induction treatment before ASCT. 21 In contrast, age, gender, type of light chain, total IgG count at ASCT and single versus tandem ASCT had no significant impact on survival. For relapse-free survival, there was no difference between myeloma patients with HZ compared with those without HZ after ASCT (Figure 2 and Supplementary Table S1 ).
Varicella zoster virus reactivation C Kamber et al
Immunologic assessments
The VZV status was analyzed using serum prospectively stored on the first day of the mobilization procedure before autologous stem cell collection. All samples were analyzed together in April 2013. Samples from 119 patients were available for both the Serion ELISA VZV IgG assay and the immunofluorescence assay for detection of IgG antibodies to VZV. By Serion Elisa VZV IgG assessment, 90.8% of all myeloma patients had specific VZV antibodies at ASCT, 3.4% had no detectable VZV antibodies and 5.9% had a borderline titer of VZV antibodies (Table 4) . Patients with lower levels of VZV antibodies before ASCT had an increased risk for HZ after ASCT (P = 0.024), whereas patients with HZ within 24 months before ASCT had higher VZV antibody levels (P = 0.009) (Figure 1c) . The level of VZV antibodies had no effect on OS (P = 0.93). The distribution of individual Serion ELISA-specific antibody levels in our cohort of Swiss myeloma patients (Figure 1d ) was comparable with a reference (healthy) population in southern Germany.
We further analyzed the same patient sera using an immunofluoresence assay. We observed, again, positivity for VZV antibodies in 89.1% and borderline immunity in 10.9% of the patients. The consistency between the immunofluoresence and the ELISA assays was 88.2%; inconsistent results were found in 14 (11.8%) patients (Table 4) .
Finally, we collected data on the level of total (unspecific) IgGs determined on the first day of the mobilization procedure before autologous stem cell collection. Patients with HZ after ASCT had lower IgG levels than patients with HZ before ASCT (P = 0.013). The total IgG level had no effect on OS (P = 0.134).
DISCUSSION
In this study, we evaluated a short-term antiviral prophylaxis using 500 mg acyclovir orally twice daily for 3 weeks following ASCT in an academic single-center cohort of 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT after first-line induction treatment. We observed that 21.5% of all patients developed at least one HZ event after ASCT, with a median HZ occurrence at 8 months after ASCT. Additional 8.5% of the patients suffered from HZ during myeloma induction treatment before ASCT.
Our study is in accordance with previous reports suggesting that HZ is frequent after autologous or allogeneic BM or peripheral blood hematopoietic SCT. The incidence of HZ at 1 year following SCT was reported to vary between 5 and 53%, 4, 17, 19, 22, 23 and specifically after autologous SCT between 8 and 30%. 3, [12] [13] [14] [15] [16] The increased risk of HZ in SCT recipients is highest during the first year following transplantation because of the diminished T-cell Varicella zoster virus reactivation C Kamber et al immunity, 3, 12, 15 and reaches a plateau by 2 or 3 years after transplantation. 3, 13, 19, 24, 25 Similarly, we observed that 28 of the 41 (68%) HZ events after ASCT in our cohort occurred in the first 12 months after ASCT, while the other 13 HZ events were observed randomly distributed during the following 24 months.
ASCT recipients are at an increased risk for viremia and visceral dissemination during HZ, which was reported to occur in approximately 10-30% of patients with severely impaired cellular immunity. 5, 9 Disseminated VZV infection can result in complications such as pneumonia, hepatitis or encephalitis, eventually manifesting as a sepsis-like syndrome in immunocompromised persons. In contrast, no patient in our cohort suffered from such complications. In accordance with reported seroprevalence rates of VZV antibodies in adult Europeans in excess of 95%, only 3.4% of the patients in our cohort lacked detectable specific VZV antibodies at ASCT and were thus potentially susceptible to primary VZV infection.
ASCT recipients conventionally receive antiviral prophylaxis to reduce the risk of herpes virus-associated diseases, including HZ; however, the duration of prophylaxis is not standardized and varies between centers. 20 Clearly, our institutional policy of antiviral prophylaxis with 500 mg acyclovir bid for 3 weeks starting on the day after ASCT is conservative. As a consequence of this study, we have modified our internal guidelines and recommend prolonged antiviral prophylaxis. Available data suggest that prolonged antiviral prophylaxis for at least 1 year after ASCT can reduce the incidence of HZ during the first 2 years after transplant. 19 Nevertheless, using this strategy the incidence of HZ remained substantially higher than in the general population (4 8% at year 2 post transplant). 19 It must be emphasized that HZ may be associated with significant symptoms. Several patients in our cohort, particularly patients with zoster ophthalmicus and/or with zoster-associated neurologic pain, described their HZ as being 'far worse than all other side effects of high-dose chemotherapy'. Disease burden was assessed as 'high' by 37% of patients with HZ and as 'rather high' by another 33%. Thus, HZ after ASCT is common and Varicella zoster virus reactivation C Kamber et al has considerable negative impact on the quality of life. Our data suggest that improving the effectiveness of antiviral prophylaxis is an unmet clinical need in the field of ASCT. Vaccination using a live attenuated VZV vaccine is licensed to prevent HZ. [26] [27] [28] [29] [30] However, it is problematic in immunocompromised patients undergoing ASCT as well as in myeloma patients during induction chemotherapy with usually considerable doses of dexamethasone. A single study evaluated the use of an inactivated form of the varicella vaccine, Varivax (Merck), in ASCT patients: patients were vaccinated four times with inactivated Varivax, a single dose 30 days prior to transplantation and doses at months 1, 2 and 3 post transplantation. 13 The authors concluded that the vaccine was 57% effective (P = 0.02) in preventing HZ. 13 Nevertheless, VZV vaccination is not routinely performed in clinical practice in ASCT patients.
A possibly more effective approach in preventing HZ after ASCT may focus on identifying patients at increased risk for VZV reactivation. Interestingly, our study suggested that myeloma patients with lower levels of specific VZV antibodies at ASCT had a greater risk for HZ after ASCT (P = 0.009), with good consistency between the ELISA and the immunofluorescence assays. Thus, myeloma patients with low/absent specific VZV antibody levels may be candidates for prolonged antiviral prophylaxis, a vaccination approach [29] [30] [31] -and/or evaluation of Ig substitution (for which the current literature provides poor evidence). However, such recommendations need to be tested in adequately powered randomized prospective studies. Given the disease burden reported by HZ-affected patients, such clarification is a medical need.
Finally, we evaluated whether VZV reactivation after ASCT is associated with outcome in myeloma patients undergoing high-dose chemotherapy with ASCT. Surprisingly, our data indicate that overall outcome is decisively more favorable in the Varicella zoster virus reactivation C Kamber et al cohort of myeloma patients with HZ after ASCT compared with patients without HZ after ASCT. Despite a comparable rate of relapsing disease, the survival rate of patients with HZ after ASCT was significantly better. Apart from the possibility of being a finding by chance, the reasons for this provocative result are unclear. One might speculate that the HZ-induced increased production of (specific and non-specific) Igs, as observed in the patients with HZ before ASCT, might have a role in increased survival. Because relapse-free survival was not altered by HZ, it seems improbable that vulnerability for the development of HZ after ASCT represents a surrogate marker for the efficacy of antimyeloma treatment. In conclusion, our findings highlight the need of increased awareness of HZ and its marked negative impact on the quality of life of myeloma patients, and they underline the need to improve antiviral prophylaxis for myeloma patients.
